{"id":"https://openalex.org/W2043955286","doi":"https://doi.org/10.1111/j.1360-0443.2005.00991.x","title":"Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)","display_name":"Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)","alternate_titles":[],"publication_year":2005,"publication_date":"2005-02-24","ids":{"openalex":"https://openalex.org/W2043955286","doi":"https://doi.org/10.1111/j.1360-0443.2005.00991.x","mag":"2043955286","pmid":"https://pubmed.ncbi.nlm.nih.gov/15730352"},"language":"en","primary_location":{"id":"doi:10.1111/j.1360-0443.2005.00991.x","doi":"https://doi.org/10.1111/j.1360-0443.2005.00991.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1360-0443.2005.00991.x","pdf_url":null,"source":{"id":"https://openalex.org/S70513841","display_name":"Addiction","issn_l":"0965-2140","issn":["0965-2140","1360-0443"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Addiction","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2043955286"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059600880","display_name":"STEVEN J. SHOPTAW","orcid":"https://orcid.org/0000-0002-3583-0026","observed_orcids":["https://orcid.org/0000-0002-3583-0026"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Steven Shoptaw","raw_affiliation_strings":["UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA. Sshoptaw@mednet.ucla.edu","UCLA Integrated Substance Abuse Programs , Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA. Sshoptaw@mednet.ucla.edu","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"UCLA Integrated Substance Abuse Programs , Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102133640","display_name":"Donnie W. Watson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210146075","display_name":"Friends Research Institute","ror":"https://ror.org/03qjb5r86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210146075"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Donnie W. Watson","raw_affiliation_strings":["Friends Research Institute, Inc., Los Angeles, CA and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Friends Research Institute, Inc., Los Angeles, CA and","institution_ids":["https://openalex.org/I4210146075"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110035365","display_name":"Chris Reiber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Chris Reiber","raw_affiliation_strings":["UCLA Integrated Substance Abuse Programs , Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Integrated Substance Abuse Programs , Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042253793","display_name":"Richard A. Rawson","orcid":"https://orcid.org/0000-0003-1180-3119","observed_orcids":["https://orcid.org/0000-0003-1180-3119"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Richard A. Rawson","raw_affiliation_strings":["UCLA Integrated Substance Abuse Programs , Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Integrated Substance Abuse Programs , Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049276409","display_name":"Margaret A. Montgomery","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Margaret A. Montgomery","raw_affiliation_strings":["National Institute on Drug Abuse, Division of Treatment Research and Development, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Institute on Drug Abuse, Division of Treatment Research and Development, Bethesda, MD, USA","institution_ids":["https://openalex.org/I1327069482"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110389623","display_name":"Maria Dorota Majewska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Maria D. Majewska","raw_affiliation_strings":["National Institute on Drug Abuse, Division of Treatment Research and Development, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Institute on Drug Abuse, Division of Treatment Research and Development, Bethesda, MD, USA","institution_ids":["https://openalex.org/I1327069482"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049281885","display_name":"Walter W Ling","orcid":"https://orcid.org/0000-0003-0664-5099","observed_orcids":["https://orcid.org/0000-0003-0664-5099"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Walter Ling","raw_affiliation_strings":["UCLA Integrated Substance Abuse Programs , Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Integrated Substance Abuse Programs , Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5059600880"],"corresponding_institution_ids":["https://openalex.org/I161318765"],"apc_list":{"value":4600,"currency":"USD","value_usd":4600},"apc_paid":null,"fwci":2.4938,"has_fulltext":false,"cited_by_count":50,"citation_normalized_percentile":{"value":0.8801984,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"100","issue":"s1","first_page":"78","last_page":"90"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.9150000214576721,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.9150000214576721,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.05389999970793724,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.006800000090152025,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cocaine-dependence","display_name":"cocaine dependence","score":0.9900000095367432},{"id":"https://openalex.org/keywords/cabergoline","display_name":"cabergoline","score":0.996999979019165},{"id":"https://openalex.org/keywords/hydergine","display_name":"hydergine","score":0.9800000190734863},{"id":"https://openalex.org/keywords/levodopa-carbidopa","display_name":"levodopa/carbidopa","score":0.9959999918937683},{"id":"https://openalex.org/keywords/dopaminergic-therapy","display_name":"dopaminergic therapy","score":0.8579999804496765},{"id":"https://openalex.org/keywords/drug-therapy","display_name":"pharmacotherapy","score":0.8759999871253967},{"id":"https://openalex.org/keywords/cocaine-craving","display_name":"cocaine craving","score":0.7670000195503235},{"id":"https://openalex.org/keywords/cocaine-metabolites","display_name":"cocaine metabolites","score":0.6919999718666077},{"id":"https://openalex.org/keywords/hiv-risk-behavior","display_name":"HIV risk behavior","score":0.8090000152587891},{"id":"https://openalex.org/keywords/employment-effects","display_name":"employment effects","score":0.45899999141693115},{"id":"https://openalex.org/keywords/drug-survival","display_name":"drug retention","score":0.414000004529953}],"concepts":[{"id":"https://openalex.org/C2779832395","wikidata":"https://www.wikidata.org/wiki/Q423308","display_name":"Cabergoline","level":4,"score":0.9254724383354187},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7604373693466187},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7131390571594238},{"id":"https://openalex.org/C2776754145","wikidata":"https://www.wikidata.org/wiki/Q71133637","display_name":"Carbidopa","level":5,"score":0.578513503074646},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5265381932258606},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4978649616241455},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4462790787220001},{"id":"https://openalex.org/C204243189","wikidata":"https://www.wikidata.org/wiki/Q1363085","display_name":"Randomization","level":3,"score":0.4362373650074005},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.419728547334671},{"id":"https://openalex.org/C2780304432","wikidata":"https://www.wikidata.org/wiki/Q300989","display_name":"Levodopa","level":4,"score":0.3922663629055023},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.383434534072876},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.14345595240592957},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.05903595685958862},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C2779064019","wikidata":"https://www.wikidata.org/wiki/Q66590068","display_name":"Prolactin","level":3,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077465","descriptor_name":"Cabergoline","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002230","descriptor_name":"Carbidopa","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004873","descriptor_name":"Ergolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007980","descriptor_name":"Levodopa","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015259","descriptor_name":"Dopamine Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019970","descriptor_name":"Cocaine-Related Disorders","qualifier_ui":"Q000534","qualifier_name":"rehabilitation","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1360-0443.2005.00991.x","doi":"https://doi.org/10.1111/j.1360-0443.2005.00991.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1360-0443.2005.00991.x","pdf_url":null,"source":{"id":"https://openalex.org/S70513841","display_name":"Addiction","issn_l":"0965-2140","issn":["0965-2140","1360-0443"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Addiction","raw_type":"journal-article"},{"id":"pmid:15730352","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15730352","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Addiction (Abingdon, England)","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G1416657037","display_name":null,"funder_award_id":"1 Y01 DA 50038","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"}],"funders":[{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":45,"referenced_works":["https://openalex.org/W92418778","https://openalex.org/W589271961","https://openalex.org/W1589814744","https://openalex.org/W1591638896","https://openalex.org/W1964388466","https://openalex.org/W1965687908","https://openalex.org/W1974456144","https://openalex.org/W1975271154","https://openalex.org/W1981727048","https://openalex.org/W1982297364","https://openalex.org/W1982641194","https://openalex.org/W1985514982","https://openalex.org/W1993243689","https://openalex.org/W2000363595","https://openalex.org/W2003726420","https://openalex.org/W2007538638","https://openalex.org/W2018303551","https://openalex.org/W2028015094","https://openalex.org/W2030967885","https://openalex.org/W2037060024","https://openalex.org/W2037327208","https://openalex.org/W2040892630","https://openalex.org/W2054901059","https://openalex.org/W2061378977","https://openalex.org/W2066245716","https://openalex.org/W2067414162","https://openalex.org/W2081760083","https://openalex.org/W2081950565","https://openalex.org/W2083405951","https://openalex.org/W2090603490","https://openalex.org/W2092652733","https://openalex.org/W2097249485","https://openalex.org/W2117713199","https://openalex.org/W2118696764","https://openalex.org/W2143199663","https://openalex.org/W2146398321","https://openalex.org/W2168445983","https://openalex.org/W2227775095","https://openalex.org/W2340133307","https://openalex.org/W2401326626","https://openalex.org/W2412299009","https://openalex.org/W2412584758","https://openalex.org/W2413927752","https://openalex.org/W2416003566","https://openalex.org/W2423303767"],"related_works":["https://openalex.org/W2050506325","https://openalex.org/W2007221331","https://openalex.org/W2072242488","https://openalex.org/W2033060965","https://openalex.org/W2025757695","https://openalex.org/W2096595409","https://openalex.org/W2069296272","https://openalex.org/W2161047816","https://openalex.org/W2047453140","https://openalex.org/W2047771595"],"abstract_inverted_index":{"AIM:":[0],"This":[1],"study":[2,238],"tested":[3],"three":[4,16,25,41],"dopaminergic":[5],"medications":[6],"against":[7],"a":[8,65,142,167,236],"common":[9],"unmatched":[10],"placebo":[11,40,140,171],"condition:":[12],"hydergine":[13],"1":[14,79],"mg":[15,24,33],"times":[17,26,42],"daily":[18,27,43],"(n":[19,28,36,44],"=":[20,29,37,45,156,159,162,189,193,196],"15);":[21,30,38],"levodopa/carbidopa":[22],"25/100":[23],"cabergoline":[31,125,225],"0.5":[32],"per":[34,81],"week":[35,82,175],"and":[39,106,116,202,209],"15)":[46],"as":[47],"potential":[48],"pharmacotherapies":[49],"for":[50,108,131,148,234],"cocaine":[51,100,111,132,153],"dependence.":[52],"DESIGN:":[53],"The":[54],"four-parallel":[55],"group,":[56],"Cocaine":[57],"Rapid":[58],"Efficacy":[59],"Screening":[60],"Trial":[61],"(CREST)":[62],"design":[63],"featured":[64],"2-week":[66],"baseline":[67,149,173],"period":[68],"followed":[69],"by":[70,213],"randomization":[71],"to":[72,123,138,174],"an":[73],"8-week":[74],"medication":[75],"condition":[76],"that":[77],"included":[78,99],"hour":[80],"of":[83,211,224,239],"cognitive":[84],"behavioral":[85],"drug":[86,109],"counseling.":[87],"A":[88],"safety":[89,223],"evaluation":[90],"was":[91],"conducted":[92],"4":[93],"weeks":[94],"after":[95,146],"termination.":[96],"MEASURES:":[97],"Outcomes":[98],"metabolites":[101,133],"measured":[102,178],"in":[103,151],"urine,":[104],"retention":[105],"self-reports":[107],"use,":[110],"craving,":[112],"clinical":[113],"improvement,":[114],"mood":[115],"HIV":[117],"risk":[118],"behaviors.":[119],"RESULTS:":[120],"Participants":[121],"assigned":[122,137],"receive":[124,139],"provided":[126],"more":[127],"urine":[128],"samples":[129],"negative":[130],"(42.4%)":[134],"than":[135],"those":[136],"(25.0%),":[141],"statistically":[143],"significant":[144,168],"difference":[145],"controlling":[147],"differences":[150],"self-reported":[152],"use":[154],"(F":[155],"2.95,":[157],"df":[158],"3;":[160],"P":[161,198],"0.05).":[163,200],"Cabergoline-treated":[164],"participants":[165],"demonstrated":[166],"improvement":[169],"over":[170],"from":[172],"8":[176],"when":[177,226],"using":[179],"the":[180,221,240],"Addiction":[181],"Severity":[182],"Index":[183],"(ASI)":[184],"employment":[185],"subscale":[186],"(overall":[187],"change":[188],"-":[190],"0.09,":[191],"SD":[192],"0.10,":[194],"t":[195],"2.36,":[197],"<":[199],"Safety":[201],"adverse":[203],"event":[204],"measures":[205],"showed":[206],"similar":[207],"rates":[208],"types":[210],"complaints":[212],"treatment":[214],"condition.":[215],"CONCLUSIONS:":[216],"These":[217],"results,":[218],"combined":[219],"with":[220,228],"apparent":[222],"used":[227],"this":[229],"population,":[230],"provide":[231],"empirical":[232],"support":[233],"conducting":[235],"larger":[237],"medication.":[241]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2043955286","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":4},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
